Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis.

[4][7] Tralokinumab was discovered by Cambridge Antibody Technology scientists[12][13][14] using protein optimization based on Ribosome Display.

[15] They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims.

[16] On 21 July 2011, MedImmune LLC initiated a Phase IIb, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma.

[21] In June 2017, Leo Pharma started phase III clinical trials with tralokinumab in atopic dermatitis.